IC3 Anticoagulants Flashcards
What are the 4 stages of hemostasis and thrombosis?
- Vasoconstriction
- Primary hemostasis - platelet aggregation
- Secondary hemostasis - thrombin activation
- Clot stabilizzation
Which stage do anticoagulants act on?
Secondary hemostasis - thrombin activation
By blocking different clotting factors in the intrinsic, extrinsic, or common pathway of the coagulation cascade
What do each of these drugs block:
- Warfarin
- Dabigatran
- Rivaroxaban
- Heparin
- LMWH (Enoxaparin)
- Warfarin: VII, IX, II, X
- Dabigatran: II
- Rivaroxaban: X
- Heparin: intrinsic, II, IX, X, XI, XII
- LMWH (Enoxaparin): X, II (lesser extent)
MOA of Warfarin
Normal physiology:
- active Vit K hydroquinone is oxidized to inactive Vit K epoxide in a step coupled to carboxylation of glutamic acid residues on coagulation factors II, VII, IX, X
- this carboxylation step activates the coagulation factors IIa, VIIa, IXa, Xa
=> Vit K activates clotting
Warfarin:
- inhibits the VKORC1 (Vit K reductase) enzyme that is responsible for reactivating oxidized inactive Vit K epoxide into reduced active Vit K hydroquinone
- hence, inhibiting activation of the coagulation factors
Reversal agent for Warfarin
Vitamin K
Onset of action of Warfarin: 24-72h
Why is there a delayed onset?
- Delayed onset due to endogenous stores/reserves of active Vit K
- Warfarin confers an initial hypercoagulable state due to depletion of protein C & S (endogenous anticoagulants)
- Protein C depletion occurs quickly, and disrupts normal inhibition of factors V and VIII
*Therefore bridging therapy with LMWH needed in VTE treatment
Metabolism of Warfarin is primarily via ____
CYP2C9
- S-Warfarin is the active enantiomer that is metablized by CYP2C9
Genetic polymorphisms in which 2 genes may cause variability in response to Warfarin
CYP2C9
VKORC1
Adverse effects of Warfarin
- bleeding
- GI SEs: dyspepsia, diarrhea, N/V
- Hirsutism, Alopecia
- cutaneous necrosis - due to reduced blood supply to adipsoe tissue, typically occurs 3-5 das after initiating tx
- hepatitis (rare) - greatest risk for >60yo, male, on warfarin for <1m, alcohol, obesity
- calciphylaxis (rare, in ESRD)
- cholesterol microemboli
Contraindications with Warfarin
- hypersensitivity
- active bleeding/risk of pathological bleeding
- recent major surgery
- severe/malignant HTN
- severe hepatic impairment (child-pugh C)
- severe renal impairment (stage 5 CKD)
- pt w bacterial endocarditis, pericarditis, pericardial effusion
- blood dyscrasias (esp bleeding/thrombocytopenia)
- pregnancy (except in women with mechanical heart valve at high risk for thromboembolism)
*For pregnancy - most teratogenic 1st trimester, 2-4 weeks before delivery
Caution with Warfarin
- Bariatric surgery - gastric bypass, gastrectomy
- Heparin-induced thrombocytopenia (inhibition of protein c synthesis may accelerate thrombotic process)
- Hepatic impairment - impair synthesis of clotting factors, reduces warfarin metabolism (incr INR)
- renal impairment
- acute infection (disruption to gut flora, febrile state => incr INR)
- thyroid disease (hyperthyroidism => incr INR)
Others:
- diverticulitis, colitis
- mild-mod HTN
- PUD within last 3m
- chronic alcohol use (dcr INR)
- drainage tubes in any orifice
MOA of dabigatran
Dabigatran and its acyl glucuronide metabolites are competitive reversible non-peptide antagonists of thrombin (factor IIa)
*Directly binds to thrombin
Dabigatran etexilate (prodrug) => Dabigatran
Dabigatran formulation and why?
Enteric coated due to low oral bioavailability
Dabigatran formulation and why?
Enteric coated due to low oral bioavailability
Reversal agent for Dabigatran
Idarucizumab
- humanized mAb that binds to dabigatran and its acyl glucuronide metabolites with higher affinity than the binding affinity of Dabigatran + Thrombin
*Dabigatran has half-life 12-17h, hence effects can be reversed in 3-5days of discontinuation
Adverse effects of Dabigatran
- bleeding
- GI symtpoms (dyspepsia, abdominal discomfort)